Adenocarcinoma, Clear Cell - 25 Studies Found

Recruiting : Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
:
  • Ovarian Clear Cell Carcinoma
  • Endometrial
    : 2016-07-22
    :
    • Drug: Nintedanib Nintedanib (B
Recruiting : A Study of ENMD-2076 in Ovarian Clear Cell Cancers
: Ovarian Clear Cell Carcinoma
: 2013-07-11
: Drug: ENMD-2076
Recruiting : Immunochemotherapy for Metastatic Renal Cell Carcinoma
: Adenocarcinoma Clear Cell
: 2005-09-26
: Drug: Capecitabine (Xeloda)
Recruiting : Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma
:
  • Ovarian Cancer
  • Adverse Effects

: 2013-03-19
: Drug: Sunitinib 37.5mg everyday from D1-D28 Other Na
Completed : Ovarian Clear Cell Adenocarcinoma Review
: [M]Ovarian Cystadenoma or Carcinoma
: 2009-01-04
Recruiting : MEDI4736 Combinations in Metastatic Renal Cell Carcinoma
:
  • Renal Clear Cell Carcinoma
  • Renal Papillary Cell Carcinoma

    • : 2016-02-22
    :
    • Drug: Savolitinib Other Names:
Completed : ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
:
  • Non-Small-Cell Lung Carcinoma
  • Renal Cell Carcinoma
  • Pancrea
    : 2003-03-16
    : Drug: ABR-217620 Starting dose: 0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level o
Active, not recruiting : Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
:
  • Fallopian Tube Clear Cell Adenocarcinoma
  • Ovarian
  • Drug: Cabozantinib S-malate Gi
Active, not recruiting : Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer
:
  • Ovarian Clear Cell Adenocarcinoma
  • Recurrent Ovarian Carcinoma : 2009-09-17
    :
    • Other: Laboratory Biomarker Analysis

Completed : AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
: Advanced Renal Cell Carcinoma
: 2007-04-26
:
  • Drug: AMG 386 3 mg/kg or 10mg/
Next >>>